Clinical Trial Update: Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing denosumab to zoledronic acid in thalassemia-induced osteoporosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Thalassemia Major

Drugs mentioned

• Denosumab (denosumab)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: Thalassemia Majors (Beta-Thalassemia Major), Osteoporosis | Phase 3 | Status: TERMINATED